Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.0K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

950
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
950
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

555
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
555
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

2.2K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.2K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

708
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
708
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Magnetoencephalography Reveals Neuroprotection of COVID-19 Vaccination in Nonhuman Primates.

VaccinesĀ·2026
Same author

Ultra-short recombinant Art v 1 immunotherapy induces rapid immune modulation in mugwort allergy: A Phase I trial.

Allergology international : official journal of the Japanese Society of AllergologyĀ·2026
Same author

One-Pot Diastereoselective Synthesis of Spiro[pyrimidine-5,8'-thiazolo[5,4-<i>f</i>]quinoline]triones and Diimidazo-pyrazinyl-bis(1,3-dimethyl-2,4,6-trioxohexahydropyrimidine-5-ylium)dihydrate as Anticancer Agents.

The Journal of organic chemistryĀ·2026
Same author

Adjuvant Strategies to Improve the Efficacy of Allergen Immunotherapy.

Journal of inflammation researchĀ·2026
Same author

In vitro evaluation of the immunostimulatory effects of PAM2CS lipopeptide-based TLR2 agonists in chicken peripheral blood mononuclear cells.

Veterinary research communicationsĀ·2026
Same author

Pyrazolo[1,5-c]quinazoline-based heterocycles exhibit potent antileishmanial activity: Mechanistic insights and toxicity profile.

Bioorganic chemistryĀ·2026

Related Experiment Video

Updated: Jun 27, 2025

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
12:02

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity

Published on: November 2, 2016

12.1K

Structure-activity relationship in NOD2 agonistic muramyl dipeptides.

Aarzoo Kamboj1, Madhuri T Patil2, Nikolai Petrovsky3

  • 1Department of Chemistry and Centre of Advanced Studies in Chemistry, Panjab University, Chandigarh, 160014, India.

European Journal of Medicinal Chemistry
|May 1, 2024
PubMed
Summary

Nucleotide-binding oligomerization domain 2 (NOD2) ligands, like muramyl dipeptide (MDP), show promise in immunity and cancer therapy. This review details structure-activity relationships to improve NOD2 agonists, overcoming MDP

Keywords:
Innate immunityMDPMuramyl dipeptideNOD2PAMPsVaccine adjuvant

More Related Videos

Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase
11:01

Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase

Published on: November 23, 2016

9.7K
Synthesis and Mass Spectrometry Analysis of Oligo-peptoids
11:44

Synthesis and Mass Spectrometry Analysis of Oligo-peptoids

Published on: February 21, 2018

10.9K

Related Experiment Videos

Last Updated: Jun 27, 2025

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
12:02

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity

Published on: November 2, 2016

12.1K
Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase
11:01

Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase

Published on: November 23, 2016

9.7K
Synthesis and Mass Spectrometry Analysis of Oligo-peptoids
11:44

Synthesis and Mass Spectrometry Analysis of Oligo-peptoids

Published on: February 21, 2018

10.9K

Area of Science:

  • Immunology
  • Medicinal Chemistry
  • Structural Biology

Background:

  • Nucleotide-binding oligomerization domain 2 (NOD2) is a key innate immune receptor recognizing bacterial components.
  • Muramyl dipeptide (MDP) is the minimal active fragment of bacterial peptidoglycan recognized by NOD2.
  • MDP exhibits vaccine adjuvant and anti-infective properties but has limitations like pyrogenicity and poor bioavailability.

Purpose of the Study:

  • To provide a comprehensive review of structure-activity relationships (SAR) for NOD2 ligands.
  • To summarize structural modifications of MDP derivatives and their impact on NOD2 agonistic activity.
  • To guide the development of improved NOD2 agonists with enhanced therapeutic potential.

Main Methods:

  • Literature review of studies on NOD2 ligands and MDP derivatives.
  • Analysis of structure-activity relationship data for various MDP analogs.
  • Synthesis and evaluation of NOD2 agonistic activity of modified MDP scaffolds.

Main Results:

  • Detailed SAR analysis reveals key structural features influencing NOD2 agonistic activity.
  • Identified specific modifications that enhance potency and improve pharmacokinetic properties of MDP derivatives.
  • Highlighted promising NOD2 ligands with potential for therapeutic applications.

Conclusions:

  • Understanding the SAR of MDP derivatives is crucial for designing effective NOD2 agonists.
  • Optimized NOD2 ligands can overcome the limitations of native MDP.
  • Further development of NOD2-targeting therapeutics holds significant promise for infectious diseases, cancer, and vaccine adjuvants.